S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Molecular Partners AG (MOLN)
Molecular Partners AG (MOLN) News

MOLN

Molecular Partners (MOLN)

Molecular Partners AG

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MOLN

1 2 3 4 5 Next >>

Date	Time	Source	Headline	Symbol	Company
05/17/2024	5:25AM	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
05/17/2024	5:25AM	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
05/17/2024	5:25AM	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
05/17/2024	5:25AM	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:MOLN	Molecular Partners AG
05/16/2024	3:00PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
05/16/2024	3:00PM	GlobeNewswire Inc.	Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program	NASDAQ:MOLN	Molecular Partners AG
04/29/2024	10:00AM	GlobeNewswire Inc.	Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action	NASDAQ:MOLN	Molecular Partners AG
04/19/2024	10:12AM	GlobeNewswire Inc.	Life Science Cares Launches in Switzerland	NASDAQ:MOLN	Molecular Partners AG
04/17/2024	10:12AM	GlobeNewswire Inc.	Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	NASDAQ:MOLN	Molecular Partners AG
03/26/2024	8:26AM	GlobeNewswire Inc.	Molecular Partners Publishes Invitation to Annual General Meeting 2024	NASDAQ:MOLN	Molecular Partners AG
03/14/2024	3:00PM	GlobeNewswire Inc.	Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023	NASDAQ:MOLN	Molecular Partners AG
03/01/2024	3:00PM	GlobeNewswire Inc.	Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations	NASDAQ:MOLN	Molecular Partners AG
01/08/2024	11:33AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
01/07/2024	3:00PM	GlobeNewswire Inc.	Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:MOLN	Molecular Partners AG
01/05/2024	3:00PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
01/05/2024	3:00PM	GlobeNewswire Inc.	Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	NASDAQ:MOLN	Molecular Partners AG
12/14/2023	12:00AM	GlobeNewswire Inc.	Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences	NASDAQ:MOLN	Molecular Partners AG
12/10/2023	11:00AM	GlobeNewswire Inc.	Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
11/14/2023	12:00AM	GlobeNewswire Inc.	Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)	NASDAQ:MOLN	Molecular Partners AG
11/03/2023	11:00AM	GlobeNewswire Inc.	Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
11/02/2023	5:01AM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
11/02/2023	1:00AM	GlobeNewswire Inc.	Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition	NASDAQ:MOLN	Molecular Partners AG
11/01/2023	1:00AM	GlobeNewswire Inc.	Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit	NASDAQ:MOLN	Molecular Partners AG
10/26/2023	3:00PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
10/26/2023	3:00PM	GlobeNewswire Inc.	Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio	NASDAQ:MOLN	Molecular Partners AG
09/13/2023	12:00AM	GlobeNewswire Inc.	Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting	NASDAQ:MOLN	Molecular Partners AG
08/24/2023	3:02PM	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MOLN	Molecular Partners AG
08/24/2023	3:00PM	GlobeNewswire Inc.	Molecular Partners Reports H1 2023 Corporate Highlights and Financials	NASDAQ:MOLN	Molecular Partners AG
06/28/2023	7:35AM	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:MOLN	Molecular Partners AG
06/28/2023	7:34AM	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:MOLN	Molecular Partners AG

Showing the most relevant articles for your search:NASDAQ:MOLN

1 2 3 4 5 Next >>

TheGlobe com (PK)

Ecare Solutions (PK)

Ronn Motor (PK)

Code Green Apparel (PK)

Enzolytics (PK)

Elite Pharmaceuticals (QB)

Music Licensing

Liquidmetal Technologies (QB)

Nexus Energy Services (PK)

Decentral Life (PK)

NioCorp Developments

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions